Brussel, Belgium

Abdeslam Bouhdid


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1996

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Abdeslam Bouhdid: Innovator in Organotin Compounds

Introduction

Abdeslam Bouhdid is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of organotin compounds, particularly in the development of novel pharmaceutical compositions. His work focuses on creating compounds that exhibit anti-tumor activities, showcasing his commitment to advancing medical science.

Latest Patents

Abdeslam Bouhdid holds two patents that highlight his innovative research. The first patent involves dibutyltin bis(dihydroxybenzoates), which are novel Sn compounds exhibiting excellent activities against various tumors. This invention also includes pharmaceutical compositions containing these compounds, particularly in aqueous solutions suitable for injection. The second patent pertains to aromatic fluorine-containing organotin compounds, which are designed to serve as anti-tumor agents. These compounds are characterized by specific chemical formulas and demonstrate potential as effective treatments in oncology.

Career Highlights

Abdeslam Bouhdid is associated with Pharmachemie B.V., where he continues to develop and refine his innovative ideas. His work has positioned him as a key figure in the pharmaceutical industry, particularly in the realm of cancer treatment.

Collaborations

He has collaborated with notable colleagues, including Marcel Gielen and Rudolph Willem, to further enhance the impact of his research and inventions.

Conclusion

Abdeslam Bouhdid's contributions to the field of organotin compounds and anti-tumor research underscore his role as a significant inventor. His patents reflect a dedication to improving therapeutic options for cancer treatment, marking him as an influential figure in pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…